A phase III trial of tipapkinogene sovacivec in patients with cervical intraepithelial neoplasia caused by human papilloma virus infection.

Trial Profile

A phase III trial of tipapkinogene sovacivec in patients with cervical intraepithelial neoplasia caused by human papilloma virus infection.

Planning
Phase of Trial: Phase III

Latest Information Update: 22 Mar 2007

At a glance

  • Drugs Tipapkinogene sovacivec (Primary)
  • Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 22 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top